25 results
424B3
ATOS
Atossa Therapeutics Inc
11 Dec 20
Prospectus supplement
7:28am
in this prospectus include, but are not limited to, statements about:
the impact of the ongoing coronavirus pandemic and the degree to which … the pandemic negatively impacts our supply chain, clinical trial enrollment and timing and our ability to access capital markets;
whether we can obtain
424B2
n7tes2hj gf
4 Feb 21
Prospectus for primary offering
4:16pm
424B3
1q84q
25 Sep 20
Prospectus supplement
5:00pm
424B3
u4820cz
8 Jan 21
Prospectus supplement
9:15am
8-K
EX-99.1
10kqs13
13 Nov 20
Atossa Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update
9:30am
424B5
33w86
21 Dec 20
Prospectus supplement for primary offering
9:16am